APO Research
Talk to an analyst

APO RESEARCH · REPORT

Luseogliflozin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Luseogliflozin Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchLuseogliflozin Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Luseogliflozin Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Luseogliflozin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Luseogliflozin Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Luseogliflozin Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Luseogliflozin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Luseogliflozin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Luseogliflozin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Luseogliflozin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Luseogliflozin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Luseogliflozin market include Taisho Toyama, Novartis, Mitsubishi Tanabe Pharma and CR Double-Crane, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Luseogliflozin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Luseogliflozin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Luseogliflozin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Luseogliflozin market size, projected growth trends, production technologies, key applications, and end-use industries.

Luseogliflozin Segment by Company

Taisho Toyama

Novartis

Mitsubishi Tanabe Pharma

CR Double-Crane

Luseogliflozin Segment by Type

2.5mg

5mg

Luseogliflozin Segment by Application

Periodontitis

Heart Disease

Diabetes

Luseogliflozin Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Luseogliflozin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Luseogliflozin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Luseogliflozin significant trends, drivers, influence factors in global and regions.

6. To analyze Luseogliflozin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Luseogliflozin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Luseogliflozin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Luseogliflozin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Luseogliflozin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Luseogliflozin industry.

Chapter 3: Detailed analysis of Luseogliflozin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Luseogliflozin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Luseogliflozin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Luseogliflozin Industry Trends Table 2. Luseogliflozin Industry Drivers Table 3. Luseogliflozin Industry Opportunities and Challenges Table 4. Luseogliflozin Industry Restraints Table 5. Global Luseogliflozin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Luseogliflozin Revenue Share by Company (2021-2026) Table 7. Global Luseogliflozin Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Luseogliflozin Sales Volume Share by Company (2021-2026) Table 9. Global Luseogliflozin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Luseogliflozin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Luseogliflozin Key Company Manufacturing Base & Headquarters Table 12. Global Luseogliflozin Company, Product Type & Application Table 13. Global Luseogliflozin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Luseogliflozin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 2.5mg Table 18. Significant Companies of 5mg Table 19. Global Luseogliflozin Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Luseogliflozin Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Luseogliflozin Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Luseogliflozin Sales Volume Share by Type (2021-2026) Table 23. Global Luseogliflozin Sales Volume Share by Type (2027-2032) Table 24. Global Luseogliflozin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Luseogliflozin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Luseogliflozin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Luseogliflozin Sales Value Share by Type (2021-2026) Table 28. Global Luseogliflozin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Periodontitis Table 30. Significant Companies of Heart Disease Table 31. Significant Companies of Diabetes Table 32. Global Luseogliflozin Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Luseogliflozin Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Luseogliflozin Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Luseogliflozin Sales Volume Share by Application (2021-2026) Table 36. Global Luseogliflozin Sales Volume Share by Application (2027-2032) Table 37. Global Luseogliflozin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Luseogliflozin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Luseogliflozin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Luseogliflozin Sales Value Share by Application (2021-2026) Table 41. Global Luseogliflozin Sales Value Share by Application (2027-2032) Table 42. Global Luseogliflozin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Luseogliflozin Sales by Region (2021-2026) & (K Units) Table 44. Global Luseogliflozin Sales Market Share by Region (2021-2026) Table 45. Global Luseogliflozin Sales by Region (2027-2032) & (K Units) Table 46. Global Luseogliflozin Sales Market Share by Region (2027-2032) Table 47. Global Luseogliflozin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Luseogliflozin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Luseogliflozin Sales Value Share by Region (2021-2026) Table 50. Global Luseogliflozin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Luseogliflozin Sales Value Share by Region (2027-2032) Table 52. Global Luseogliflozin Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Luseogliflozin Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Luseogliflozin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Luseogliflozin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Luseogliflozin Sales by Country (2021-2026) & (K Units) Table 57. Global Luseogliflozin Sales Market Share by Country (2021-2026) Table 58. Global Luseogliflozin Sales by Country (2027-2032) & (K Units) Table 59. Global Luseogliflozin Sales Market Share by Country (2027-2032) Table 60. Global Luseogliflozin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Luseogliflozin Sales Value Market Share by Country (2021-2026) Table 62. Global Luseogliflozin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Luseogliflozin Sales Value Market Share by Country (2027-2032) Table 64. Taisho Toyama Company Information Table 65. Taisho Toyama Business Overview Table 66. Taisho Toyama Luseogliflozin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Taisho Toyama Luseogliflozin Product Portfolio Table 68. Taisho Toyama Recent Development Table 69. Novartis Company Information Table 70. Novartis Business Overview Table 71. Novartis Luseogliflozin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis Luseogliflozin Product Portfolio Table 73. Novartis Recent Development Table 74. Mitsubishi Tanabe Pharma Company Information Table 75. Mitsubishi Tanabe Pharma Business Overview Table 76. Mitsubishi Tanabe Pharma Luseogliflozin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Mitsubishi Tanabe Pharma Luseogliflozin Product Portfolio Table 78. Mitsubishi Tanabe Pharma Recent Development Table 79. CR Double-Crane Company Information Table 80. CR Double-Crane Business Overview Table 81. CR Double-Crane Luseogliflozin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. CR Double-Crane Luseogliflozin Product Portfolio Table 83. CR Double-Crane Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Luseogliflozin Distributors List Table 87. Luseogliflozin Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Luseogliflozin Product Image Figure 2. Global Luseogliflozin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Luseogliflozin Sales (2021-2032) & (K Units) Figure 5. Global Luseogliflozin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Luseogliflozin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 2.5mg Image Figure 10. 5mg Image Figure 11. Global Luseogliflozin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Luseogliflozin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Luseogliflozin Sales Volume Share by Type (2021-2032) Figure 14. Global Luseogliflozin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Luseogliflozin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Luseogliflozin Sales Value Share by Type (2021-2032) Figure 17. Periodontitis Image Figure 18. Heart Disease Image Figure 19. Diabetes Image Figure 20. Global Luseogliflozin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Luseogliflozin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Luseogliflozin Sales Volume Share by Application (2021-2032) Figure 23. Global Luseogliflozin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Luseogliflozin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Luseogliflozin Sales Value Share by Application (2021-2032) Figure 26. Global Luseogliflozin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Luseogliflozin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Luseogliflozin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Luseogliflozin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Luseogliflozin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Luseogliflozin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Luseogliflozin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Luseogliflozin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Luseogliflozin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Luseogliflozin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Luseogliflozin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Luseogliflozin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Luseogliflozin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Luseogliflozin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Luseogliflozin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5mg
  • 5mg
Applications
  • Periodontitis
  • Heart Disease
  • Diabetes
Companies covered
  • Taisho Toyama
  • Novartis
  • Mitsubishi Tanabe Pharma
  • CR Double-Crane

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Luseogliflozin Sales Value (2021-2032)
  4. 1.2.2 Global Luseogliflozin Sales Volume (2021-2032)
  5. 1.2.3 Global Luseogliflozin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Luseogliflozin Market Dynamics
  1. 2.1 Luseogliflozin Industry Trends
  2. 2.2 Luseogliflozin Industry Drivers
  3. 2.3 Luseogliflozin Industry Opportunities and Challenges
  4. 2.4 Luseogliflozin Industry Restraints
3 Luseogliflozin Market by Company
  1. 3.1 Global Luseogliflozin Company Revenue Ranking in 2025
  2. 3.2 Global Luseogliflozin Revenue by Company (2021-2026)
  3. 3.3 Global Luseogliflozin Sales Volume by Company (2021-2026)
  4. 3.4 Global Luseogliflozin Average Price by Company (2021-2026)
  5. 3.5 Global Luseogliflozin Company Ranking (2024-2026)
  6. 3.6 Global Luseogliflozin Company Manufacturing Base and Headquarters
  7. 3.7 Global Luseogliflozin Company Product Type and Application
  8. 3.8 Global Luseogliflozin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Luseogliflozin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Luseogliflozin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Luseogliflozin Market by Type
  1. 4.1 Luseogliflozin Type Introduction
  2. 4.1.1 2.5mg
  3. 4.1.2 5mg
  4. 4.2 Global Luseogliflozin Sales Volume by Type
  5. 4.2.1 Global Luseogliflozin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Luseogliflozin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Luseogliflozin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Luseogliflozin Sales Value by Type
  9. 4.3.1 Global Luseogliflozin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Luseogliflozin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Luseogliflozin Sales Value Share by Type (2021-2032)
5 Luseogliflozin Market by Application
  1. 5.1 Luseogliflozin Application Introduction
  2. 5.1.1 Periodontitis
  3. 5.1.2 Heart Disease
  4. 5.1.3 Diabetes
  5. 5.2 Global Luseogliflozin Sales Volume by Application
  6. 5.2.1 Global Luseogliflozin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Luseogliflozin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Luseogliflozin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Luseogliflozin Sales Value by Application
  10. 5.3.1 Global Luseogliflozin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Luseogliflozin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Luseogliflozin Sales Value Share by Application (2021-2032)
6 Luseogliflozin Regional Sales and Value Analysis
  1. 6.1 Global Luseogliflozin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Luseogliflozin Sales by Region (2021-2032)
  3. 6.2.1 Global Luseogliflozin Sales by Region: 2021-2026
  4. 6.2.2 Global Luseogliflozin Sales by Region (2027-2032)
  5. 6.3 Global Luseogliflozin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Luseogliflozin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Luseogliflozin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Luseogliflozin Sales Value by Region (2027-2032)
  9. 6.5 Global Luseogliflozin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Luseogliflozin Sales Value (2021-2032)
  12. 6.6.2 North America Luseogliflozin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Luseogliflozin Sales Value (2021-2032)
  15. 6.7.2 Europe Luseogliflozin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Luseogliflozin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Luseogliflozin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Luseogliflozin Sales Value (2021-2032)
  21. 6.9.2 South America Luseogliflozin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Luseogliflozin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Luseogliflozin Sales Value Share by Country, 2025 VS 2032
7 Luseogliflozin Country-level Sales and Value Analysis
  1. 7.1 Global Luseogliflozin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Luseogliflozin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Luseogliflozin Sales by Country (2021-2032)
  4. 7.3.1 Global Luseogliflozin Sales by Country (2021-2026)
  5. 7.3.2 Global Luseogliflozin Sales by Country (2027-2032)
  6. 7.4 Global Luseogliflozin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Luseogliflozin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Luseogliflozin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Luseogliflozin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Luseogliflozin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Luseogliflozin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Luseogliflozin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Luseogliflozin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Luseogliflozin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Luseogliflozin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Luseogliflozin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Luseogliflozin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Luseogliflozin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Luseogliflozin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Luseogliflozin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Luseogliflozin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Luseogliflozin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Luseogliflozin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Luseogliflozin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Luseogliflozin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Luseogliflozin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Luseogliflozin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Luseogliflozin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Luseogliflozin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Luseogliflozin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Luseogliflozin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Luseogliflozin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Luseogliflozin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Luseogliflozin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Luseogliflozin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Luseogliflozin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Luseogliflozin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Luseogliflozin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Luseogliflozin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Taisho Toyama
  2. 8.1.1 Taisho Toyama Company Information
  3. 8.1.2 Taisho Toyama Business Overview
  4. 8.1.3 Taisho Toyama Luseogliflozin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Taisho Toyama Luseogliflozin Product Portfolio
  6. 8.1.5 Taisho Toyama Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Luseogliflozin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Luseogliflozin Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Mitsubishi Tanabe Pharma
  14. 8.3.1 Mitsubishi Tanabe Pharma Company Information
  15. 8.3.2 Mitsubishi Tanabe Pharma Business Overview
  16. 8.3.3 Mitsubishi Tanabe Pharma Luseogliflozin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mitsubishi Tanabe Pharma Luseogliflozin Product Portfolio
  18. 8.3.5 Mitsubishi Tanabe Pharma Recent Developments
  19. 8.4 CR Double-Crane
  20. 8.4.1 CR Double-Crane Company Information
  21. 8.4.2 CR Double-Crane Business Overview
  22. 8.4.3 CR Double-Crane Luseogliflozin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CR Double-Crane Luseogliflozin Product Portfolio
  24. 8.4.5 CR Double-Crane Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Luseogliflozin Value Chain Analysis
  2. 9.1.1 Luseogliflozin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Luseogliflozin Sales Mode & Process
  6. 9.2 Luseogliflozin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Luseogliflozin Distributors
  9. 9.2.3 Luseogliflozin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst